Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In Sam's defense, how can one not comprehend another investor's somewhat positive take on this company based on the current fact that the company, despite such profound troubles in the past, still exists; it still is publicly traded, and it now seems headed toward eventual FDA approval.
The filters now function as intended, and Chemostat works as intended, and the company is valued as if the market believes those statements should be followed by question marks.
Should have stayed loyal. $BIOL stopped being fun immediately when I invested, while $DCTHD has awoken. The BigStud guy is the only poster I remember who not only expected it to drop on Jan 2, but called the amount it would drop to that day. I didn't take his advice then. Nor now for that matter. Next time, though...
Spread on BIOL (a recent reverse split) is interesting. $1.80 (now $2.15) on the BID, $4 on the ASK.
A reverse split where no one is selling.
Now this is probably how $DCTHD investors should do it next go-around.
Anytime that revenues is mentioned here, let's remember the press release from last summer which mentioned revenues for its surge protector were way exceeding their target expectations ... and yet, by year's end, had they sold more than 100 ? Had they only expected to sell 2?
Of course, believing we might get a bad offering is an obviously sensible thought.
If a company has a market cap in the past year which fluctuated between 1 and 150 million, and if the general health of the company improved more as the market cap went down, then what should due diligence tell us? How much would it help an investor in his or her gamble? And why should new investors be taking advice from some people here who claim to have held through multiple reverse splits without ever selling?
Great new press release:
Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
8:00 AM ET, 05/07/2018 - GlobeNewswire
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). Duke Medical Center in Durham, North Carolina is the first cancer center to open for patient enrollment. Dr. Sabino Zani, a surgical oncologist with Duke Medical Center, is serving as the principal investigator for the trial in the United States.
The trial, entitled A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma, (the ALIGN Trial) will seek to enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe. The trial is being conducted under a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration (FDA) in March 2017. Under the terms of the SPA, the primary endpoint is overall survival (OS) and secondary and exploratory endpoints include safety, progression-free survival (PFS), overall response rate (ORR) and quality-of-life measures. The SPA agreement indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS.
“The ALIGN Trial is based on a strong efficacy signal observed in the ICC tumor type through our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems. “The sequential design of the therapies under investigation in the trial will allow us to minimize capital investment requirements in 2018. We are also leveraging our existing network of trial sites from our FOCUS Phase 3 trial to rollout the trial protocol as efficiently as possible, and intend to conduct the trial in a financially prudent manner. In this orphan population where there exists a huge unmet need, this trial provides us with a second pathway to commercial drug approval in the United States, and if successful we believe will be an important value driver for the Company.”
This is my memory of Friday. This is a trade that's very much about the float, and at this moment very little else, and I continue to expect a great day. GLTA.
Stock dropped about 90 percent since news of the RS and the actual RS before Friday's good day. It's still about 70 percent below the date when the press release announced the last RS.
It will happen again with garbage company $RSLS (formerly $ETRM, and about to do another RS too) -- people overestimate how far crap needs to drop before it becomes fertilizer. (Not sure if metaphor worked, but keeping it in.)
They (Delcath) use Chemostat to focus on a rare liver cancer. But Chemostat has the potential as a procedure to be used to prolong the life of people with different cancers. Why do the patents not matter when Delcath can monetarily benefit from more companies believing in Chemostat and expanding the process into other areas? Delcath cannot afford to do it at this time, certainly, but others could, correct?
If they do another horrible financing, I simply don't expect it to happen before the CEO's Tuesday presentation. It may have happened before, but I think it would be embarrassing to hype one's product on the day the stock drops 80 percent from an offering that values it like a placebo.
And the reason to do this (what you suggest in your post) would be to assume the lenders in last financing were thrilled by the company's need to refinance a few months later. When Delcath mentioned almost immediately after last financing that they would need another financing, as well as an RS, do you think that was to spite PIs or the recent institutional lenders? I think lenders played hardball, and Delcath played hardball back. Or I think that's a possibility, at least.
If market cap remains this low, then Delcath (not the lenders/investors) will likely choose another piecemeal financing route, with expectations for yet another financing the next month, which definitely won't do wonders for the PPS. (And since it's an equity offering, lenders should at least care about that.)
Compay has shown in the past they'd rather not be acquired; why would they much rather cede 95 percent of outstanding shares to hedge funds and institutional investors?
Lenders will benefit more from a loan that covers the whole Phase 3, IMO, but the only way for that to happen without Delcath ceding more or less total control of its own company is through a much higher market cap (or else through participating themselves in this next financing, which won't happen most likely, but IMO should).
If they were already in negotiations, though, would they be allowed to buy shares of their own company? I know they're not invested, and have historically avoided stock option rewards under the excuse of the need for shares in financing deals, but if they genuinely were in negotiations with an interested party, they'd be disallowed from buying shares...
The low floater aspect is a very differentiating aspect between this "ascent" and some prior moves.
IMO, if an entity or two did acquire enough shares in Delcath to be able to push it up or down at their will, what would be the incentive of bringing it down (on no news) except to accumulate?
And while people seem to disregard the return of their patents to Delcath, they definitely weren't an acquirable company until they got their patents back. Now, with a low float, zero convertibles, patents, and a lack of both debt and cash, there is at least reason to believe that getting acquired is a possibility.
Also, P-Mike used to say in posts here that they would need to raise their market cap quite a bit before they would sell company. While such would then suggest that Delcath is partly behind the price movement on Friday (which I personally doubt), doesn't this appear to be a ripe time for that pursuit of a higher market cap to happen?
Why did the Friday ascent happen?
According to the award-winning Oracle Dispatch:
"While it is difficult to nail down the precise catalyst for the move, we would pin it down to a combination of the company’s announcement Friday morning that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of the company, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference next week as well as the company’s announcement a day earlier that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. According to this earlier release, “the DSMB has again recommended that the study continue without modification.”
http://legacy-assignments.uspto.gov/assignments/assignment-pat-45624-355.pdf
https://assignment.uspto.gov/patent/index.html#/patent/search/resultAbstract?id=9707331&type=patNum
Here is the updated patent information of Delcath that H2004 provided us with.
We'll find out next week how it trades, with me admittedly quite optimistic. If it goes down on no news, I'll definitely add more. Look forward to Monday, and best to all.
Agree, and as long as there is no financing news before 9:30 AM, then this remains a low-float stock with an entity or two most likely holding enough shares to do as they wish with the PPS.
What if we get a PR regarding the return of their patents on Monday?
Comparisons seem pointless, but when $ETRM shot up to $30, I think it was able to secure an offering at around $7. A huge drop but still it came well above the reverse split price, so I think there's genuine hope here that the stock, one shoots up more, and that the offering price, while still much lower than whatever peak stock price we get, remains possibly even above our current share price, thus helping to keep it a volatile low floater for a while.
I think it is simply one entity or two controlling stock price movement. They took it to $1.90 from $1.30 in minutes, then sent it back down again quickly too. Always had lots on BID, though, whenever the price was taken down, which made me hope (correctly for once) that the price would rebound back, ec.
Whomever is manipulating the stock upward probably has a lot of shares. Enough to withstand the selling pressure from those cashing in at end of day.
And if they are rich, I don't think they mind getting richer. And I doubt they're very conservative investors either, as they're here.
The Lord our God knows.
Anyway, it's a low-floater, and there's a lot of excitement about our CEO's presentation next week.
Whatever happens here, I like your philosophy. Am still holding -- still refreshing my screen almost every second.
I was curious about your trading strategy, etc. Thanks. I think I am still haunted by getting out at 2.4 cents when it did that run over 30 cents this previous summer. I don't expect a run like that, but I've seen a lot of garbage low floats soar this week on Stocktwits, and I am willing to let some money ride and see where it goes. If they don't announce a financing afterhrs or before Monday's bell, I see it running another day...
This the one stock where people post more on a routine, down day that on a day when the stock seems primed to double, etc.
thanks for the update.
First time in my life, I think, that my two primary investments are both popping hard at the same time.
2 press releases on back to back days for an extremely low float stock.
Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
9:29 AM ET, 05/04/2018 - GlobeNewswire
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York. Dr. Simpson’s presentation details are as follows:
Panel Presentation:
Session: Disruptive Injectables & OncologyDate and Time: Tuesday, May 8 at 1:45-2:45 p.m. ESTLocation: Track 2 – Room C/D
Corporate Presentation:
Date and Time: Tuesday, May 8 at 3:25-3:45 p.m. ESTLocation: Room A/B
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:Delcath Investor RelationsEmail: investorrelations@delcath.com
Source: Delcath Systems, Inc.
A second ago there was 15000 shares on the BID. Now only 14999.
So the interest is there.
$IMTE (a NASDAQ low-float 3D company with about 3 million shares) jumped over 3500 percent yesterday on no news.
We have too few shares to be in a trading range IMO. Stock may do nothing, but there's no way to predict what will happen right now IMO just as there was no way to predict the rise of $IMTE yesterday.
They listed the offering a while ago -- and announced that they'd be out of money by end of May too. They have never tried to get a financing through this close to running out of funds. Either they finance very soon, or something new may be coming IMO.
Now you are hoping for the company market cap to drop to $100,000 prior to a financing. That is a new development.
In the past, shareholders were burned by a stock with more shares, at a far higher market cap. If some entity invests $100,000 here, they'd likely make a million quick through stock manipulation. It would have cost them a lot more to try to manipulate stock in the past.
The positive that I take from PR is that the company actually would like the PPS to go up. They could have withheld the news for a few days if they so chose, but they didn't.
I don't see you as too negative anymore -- but it was nice to see the company make an effort.
Has there ever been a one million dollar MC company with Delcath's track record that can secure a $20 million loan on even unfavorable terms? As one who lost $20000+ so far here, hoping to learn $20000+ in the way the market works as I follow the rest of this story.
thanks... will do that.
Why would any major company have alliances/partnerships with a company so riddled with debt ? What's in it for them? Has anyone wondered that? Tri-cascade cannot afford customer support or updates to its products, so how could another company somehow see the potential behind them? And as for their "design" patent or the trademark of the SkiQ name, why is there such imagined value for these items? With APPLE, Google, and AMAzon all making smart products themselves, what makes this poorly run company so special?
At Delcath, most everyone on that board wants the CEO in jail. Here, an equally reprehensible CEO gets tagged with the genius label while it's actually many of the posters here who are the only thing making this stock run.
You should demand a lot more out of Max Li.
Why is there a reason to be optimistic until financings go forward? How could you personally re-invest until you have some idea whether you can hold your shares for more than a few hours? It's hard to know how cheap this stock is until it gets fully funded for Phase 3.
I think the financing will happen almost immediately after split. A 500/1 RS at current prices would make stock $2.50, and perhaps they will do financing once more at $2.
That will soften the inevitable decline that always happens with RS, but still won't be taken kindly if it happens. Then, after a few days, who knows? If they can get all $20 million from the financing, it likely will have some green days in the future.